Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials

J Paul Banga, Claus H Nielsen, Jacqueline A Gilbert, Daniel El Fassi, Laszlo Hegedus

    20 Citations (Scopus)

    Abstract

    Most current approaches for treating Graves' disease are based essentially upon regimes developed nearly 50 years ago. Moreover, therapeutic approaches for complications such as thyroid-associated ophthalmopathy (TAO) and dermopathy are singularly dependent on conventional approaches of nonspecific immunosuppression. The recent development of an induced model of experimental Graves' disease, although incomplete as it lacks the extrathyroidal manifestations, provided opportunities to investigate immune intervention strategies, including influence upon the autoreactive B and T cell players in the autoimmune process. These major advances are generating new possibilities for therapeutic interventions for patients with Graves' disease and TAO.
    Original languageEnglish
    JournalThyroid
    Volume18
    Issue number9
    Pages (from-to)973-81
    Number of pages9
    ISSN1050-7256
    DOIs
    Publication statusPublished - 1 Sept 2008

    Fingerprint

    Dive into the research topics of 'Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials'. Together they form a unique fingerprint.

    Cite this